This article was originally published in The Gray Sheet
Executive SummaryOffer to purchase Digene is extended to midnight April 25, with the possibility that the deadline will be further extended. Approximately 10.4 mil. shares of Digene common stock, representing 58% of the total outstanding, have been tendered and not withdrawn pursuant to the offer. Cytyc and Digene each received a formal request for additional information from the Federal Trade Commission following the initial acquisition proposal in mid-February (1"The Gray Sheet" Feb. 25, 2002, p. 3). The firms say they are "responding expeditiously"...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.